Sinir-Kas ve Sinir Kas Kavşağı Hastalıkları

Gündüz NE. Activity Limitation and Functional Assessment in Neuromuscular Diseases: Results of a Tertiary Center. Fiziksel Tıp Ve Rehabilitasyon Bilimleri Dergisi. 2023;26(2):199–205.

Yeldan İ, Aslan GK. Nöromusküler Hastalıklarda Solunum Fonksiyonlarının Değerlendirilmesi: Derleme. Sağlık Bilimleri Ve Meslekleri Dergisi. 2014;1(2):127.

Molotsky E, Liu Y, Lieberman AP, Merry DE. Neuromuscular Junction Pathology Is Correlated With Differential Motor Unit Vulnerability in Spinal and Bulbar Muscular Atrophy. Acta Neuropathol Commun. 2022;10(1).

Monti RJ, Roy RR, Edgerton VR. Role of Motor Unit Structure in Defining Function. Muscle Nerve. 2001;24(7):848–66.

Rocha MC, Pousinha PA, Correia A, Sebastião AM, Ribeiro JA. Early Changes of Neuromuscular Transmission in the SOD1(G93A) Mice Model of ALS Start Long Before Motor Symptoms Onset. PLoS One. 2013;8(9):e73846.

Tintignac L, Brenner HR, Rüegg MA. Mechanisms Regulating Neuromuscular Junction Development and Function and Causes of Muscle Wasting. Physiol Rev. 2015;95(3):809–52.

Ortíz-Benítez RE, Carrillo-Torres O, Mendoza-Escoto VM, Garduño-Prevost P, Alcazar-Castro J. Perioperative Management of the Patient With Myasthenia Gravis. Revista Médica del Hospital General de México. 2019;82(2).

Pollitt C, Anderson L V, Pogue R, Davison K, Pyle A, Bushby K. The Phenotype of Calpainopathy: Diagnosis Based on a Multidisciplinary Approach. Neuromuscular Disorders. 2001;11(3):287–96.

Bushby K, Finkel RS, Birnkrant DJ, Case LE, Clemens PR, Cripe LH, et al. Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Pharmacological and Psychosocial Management. Lancet Neurol. 2010;9(1):77–93.

Nance J. Spinal Muscular Atrophy. Continuum Lifelong Learning in Neurology. 2020;26(5):1348–68.

VanderPluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical Characteristics of Pediatric Myasthenia: A Surveillance Study. Pediatrics. 2013;132(4):e939–44.

Daack-Hirsch S, Holtzer C, Cunniff C. Parental Perspectives on the Diagnostic Process for Duchenne and Becker Muscular Dystrophy. Am J Med Genet A. 2013;161(4):687–95.

Jones TI, Yan C, Sapp PC, McKenna‐Yasek D, Kang PB, Quinn C, et al. Identifying Diagnostic DNA Methylation Profiles for Facioscapulohumeral Muscular Dystrophy in Blood and Saliva Using Bisulfite Sequencing. Clin Epigenetics. 2014;6(1).

Segarra-Casas A, Domínguez‐González C, Hernández-Laín A, Sánchez-Calvín MT, Camacho A, Rivas E, et al. Genetic Diagnosis of Duchenne and Becker Muscular Dystrophy Through mRNA Analysis: New Splicing Events. J Med Genet. 2022;60(6):615–9.

Ricci G, Mele F, Govi M, Ruggiero L, Sera F, Vercelli L, et al. Large Genotype–phenotype Study in Carriers of D4Z4 Borderline Alleles Provides Guidance for Facioscapulohumeral Muscular Dystrophy Diagnosis. Sci Rep. 2020;10(1).

Nahrel DR, Kosam D. Duchenne Muscular Dystrophy in a Female Child With Turner Syndrome: A Case Report. International Journal of Medical Research and Review. 2014;2(3):262–6.

Pane M, Scalise R, Berardinelli A, D’Angelo MG, Ricotti V, Alfieri P, et al. Early Neurodevelopmental Assessment in Duchenne Muscular Dystrophy. Neuromuscular Disorders. 2013;23(6):451–5.

Hendawy MTE, Marzouk I, Omr TE, Elmaksoud MA. Quality of Life Assessment in Patients With Duchenne Muscular Dystrophy. Int J Health Sci (Qassim). 2022;15040–9.

Koeks Z, Bladen CL, Salgado D, Zwet EW v., Pogoryelova O, McMacken G, et al. Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients From the TREAT-NMD DMD Global Database. J Neuromuscul Dis. 2017;4(4):293–306.

Kern R, Carvell K, Gupta A, Verma S. Seated Outcome Measures in Children With Duchenne Muscular Dystrophy. Pediatric Physical Therapy. 2022;34(3):375–80.

Soim A, Wallace B, Whitehead N, Smith MGH, Mann JR, Thomas S, et al. Health Profile of Preterm Males With Duchenne Muscular Dystrophy. J Child Neurol. 2021;36(12):1095–102.

Parvatiyar MS, Marshall JL, Nguyen RT, Jordan MC, Richardson VA, Roos KP, et al. Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy–Associated Cardiomyopathy. J Am Heart Assoc. 2015;4(12).

Fox D, Kumar A, West NA, DiRienzo AG, James KA, Oleszek J. Trends With Corticosteroid Use in Males With Duchenne Muscular Dystrophy Born 1982-2001. J Child Neurol. 2014;30(1):21–6.

Ryder S, Leadley RM, Armstrong N, Westwood M, Kock S d., Butt T, et al. The Burden, Epidemiology, Costs and Treatment for Duchenne Muscular Dystrophy: An Evidence Review. Orphanet J Rare Dis. 2017;12(1).

Biggar WD, Skalsky AJ, McDonald C. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2022;9(4):463–76.

Liaqat ST. Overview of Muscular Dystrophy, It’s Types, Symptoms, Management and Possible Treatment. Pure and Applied Biology. 2023;12(1).

Butterfield RJ, Krikov S, Conway KM, Johnson NE, Matthews DJ, Phan H, et al. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet. Muscle Nerve. 2022;66(1):15–23.

Danišovič Ľ, Culenova M, Csöbönyeiová M. Induced Pluripotent Stem Cells for Duchenne Muscular Dystrophy Modeling and Therapy. Cells. 2018;7(12):253.

Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes L, Miller N, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy. JAMA Neurol. 2020;77(9):1122.

Mbakam CH, Lamothe G, Tremblay JP. Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy. Front Med (Lausanne). 2022;9.

Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. Muscle Nerve [Internet]. 2024 Jan 1 [cited 2025 Jan 1];69(1):93–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.27955

McMillan HJ, Lochmüller H. Sustained clinical benefit following systemic gene replacement therapy in Duchenne muscular dystrophy. Muscle Nerve. 2024 Jan 1;69(1):4–6.

Šamija RK, Plejić M. Duchenne Muscular Dystrophy: Clinical and Therapeutic Approach. 2023;

Yoon JA, Park HE, Kim J, Son J, Shin YB. Cardiac and Pulmonary Management Status of Duchenne Muscular Dystrophy in South Korea Based on Data From the National Health Insurance Database. Journal of Clinical Neurology. 2022;18(5):522.

Bennett JS, Kertesz NJ. Management of Rhythm Disorders in Duchenne Muscular Dystrophy: Is Sudden Death a Cardiac or Pulmonary Problem? Pediatr Pulmonol. 2021;56(4):760–5.

Komaki H, Maegaki Y, Matsumura T, Shiraishi K, Awano H, Nakamura A, et al. Early Phase 2 Trial of TAS‐205 in Patients With Duchenne Muscular Dystrophy. Ann Clin Transl Neurol. 2020;7(2):181–90.

Pascual‐Morena C, Cavero‐Redondo I, Álvarez‐Bueno C, Mesas AE, Pozuelo‐Carrascosa DP, Martínez‐Vizcaíno V. Restorative Treatments of Dystrophin Expression in Duchenne Muscular Dystrophy: A Systematic Review. Ann Clin Transl Neurol. 2020;7(9):1738–52.

Köken ÖY, Kucur O, Taşkiran C, Öztoprak Ü, Sel ÇG, Aksoy E, et al. Clinical Features and Quality of Life in Duchenne and Becker Muscular Dystrophy Patients From a Tertiary Center in Turkey. Güncel Pediatri. 2021;19(1):15–22.

Magot A. Diagnosis and Management of Becker Muscular Dystrophy: The French Guidelines. J Neurol. 2023;270(10):4763–81.

Clemens PR. Findings From the Longitudinal CINRG Becker Natural History Study. J Neuromuscul Dis. 2024;11(1):201–12.

Aikawa T, Takeda A, Oyama‐Manabe N, Naya M, Yamazawa H, Koyanagawa K, et al. Progressive Left Ventricular Dysfunction and Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy: A Longitudinal Cardiovascular Magnetic Resonance Study. Pediatr Cardiol. 2018;40(2):384–92.

Canessa EH, Goswami M V, Alayi TD, Hoffman EP, Hathout Y. Absolute Quantification of Dystrophin Protein in Human Muscle Biopsies Using Parallel Reaction Monitoring (PRM). Biol Mass Spectrom. 2019;55(2).

Lee AY, Moon JW, Yü J, Kho C. MicroRNAs in Dystrophinopathy. Int J Mol Sci. 2022;23(14):7785.

Birnkrant DJ, Bushby K, Bann C, Alman BA, Apkon S, Blackwell AG, et al. Diagnosis and Management of Duchenne Muscular Dystrophy, Part 2: Respiratory, Cardiac, Bone Health, and Orthopaedic Management. Lancet Neurol. 2018;17(4):347–61.

Woodcock IR, Fraser L, Norman P, Pysden K, Manning S, Childs A. The Prevalence of Neuromuscular Disease in the Paediatric Population in Yorkshire, UK; Variation by Ethnicity and Deprivation Status. Dev Med Child Neurol. 2016;58(8):877–83.

Lai Y, Duan D. Progress in Gene Therapy of Dystrophic Heart Disease. Gene Ther. 2012;19(6):678–85.

Kuno A, Tanno M, Horio Y. The Effects of Resveratrol and SIRT1 Activation on Dystrophic Cardiomyopathy. Ann N Y Acad Sci. 2015;1348(1):46–54.

Lambert JT, Darmahkasih A, Horn PS, Rybalsky I, Shellenbarger K, Tian C, et al. Neurodevelopmental, Behavioral, and Emotional Symptoms in Becker Muscular Dystrophy. Muscle Nerve. 2019;61(2):156–62.

Laurila P, Luan P, Wohlwend M, Zanou N, Crisol BM, Lima TI, et al. Inhibition of Sphingolipid De Novo Synthesis Counteracts Muscular Dystrophy. Sci Adv. 2022;8(4).

Pezzoni L. Cognitive Abnormalities in Becker Muscular Dystrophy: A Mysterious Link Between Dystrophin Deficiency and Executive Functions. Neurological Sciences. 2023;45(4):1691–8.

Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, et al. The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia. Hum Mutat. 2013;34(11):1449–57.

Burch PM, Pogoryelova O, Goldstein RA, Bennett D, Guglieri M, Straub V, et al. Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy. J Neuromuscul Dis. 2015;2(3):241–55.

Takeuchi F, Komaki H, Nakamura H, Yonemoto N, Kashiwabara K, Kimura E, et al. Trends in Steroid Therapy for Duchenne Muscular Dystrophy in Japan. Muscle Nerve. 2016;54(4):673–80.

Barreo FS. Targeted Suppression of a Dystrophin Pseudo-Exon Using Antisense Oligonucleotides. J Genet Syndr Gene Ther. 2014;05(04).

Marden JR, Santos C, Pfister B, Able R, Lane HC, Somma M, et al. Steroid Switching in Dystrophinopathy Treatment: A US chart Review of Patient Characteristics and Clinical Outcomes. J Comp Eff Res. 2021;10(14):1065–78.

McDonald C, Sajeev G, Yao Z, McDonnell E, Elfring GL, Souza MF d., et al. Deflazacort vs Prednisone Treatment for Duchenne Muscular Dystrophy: A Meta‐analysis of Disease Progression Rates in Recent Multicenter Clinical Trials. Muscle Nerve. 2019;61(1):26–35.

Dubinin M V, Talanov EY, Tenkov KS, Starinets VS, Belosludtseva N V, Belosludtsev KN. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy. Int J Mol Sci. 2020;21(22):8763.

Hoffman EP, Reeves EK, Damsker JM, Nagaraju K, McCall JM, Connor E, et al. Novel Approaches to Corticosteroid Treatment in Duchenne Muscular Dystrophy. Phys Med Rehabil Clin N Am. 2012;23(4):821–8.

Yilmaz A, Gökçeoğlu AU, Talim B, Bakir A, ATAY N. Limb Girdle Muskuler Distrofi Tip 2a: Vaka Sunumu. Turkish Journal of Pediatric Disease. 2022;1–4.

Ullah A, Lin Z, Younus M, Shafiq S, Khan S, Rasheed M, et al. Homozygous Missense Variant in POPDC3 Causes Recessive Limb‐girdle Muscular Dystrophy Type 26. J Gene Med. 2022;24(4).

Barton ER, Pacak CA, Stoppel WL, Kang PB. The Ties That Bind: Functional Clusters in Limb-Girdle Muscular Dystrophy. Skelet Muscle. 2020;10(1).

Zhang C, Zheng X, Lyu D, Xu L, Che F, Liu S. Compound heterozygous CAPN3 variants identified in a family with limb-girdle muscular dystrophy recessive 1. Mol Med Rep. 2021;23(6).

Becker N, Moore SA, Jones KA. The Inflammatory Pathology of Dysferlinopathy Is Distinct From Calpainopathy, Becker Muscular Dystrophy, and Inflammatory Myopathies. Acta Neuropathol Commun. 2022;10(1).

Marchetti G, Valenti L, Torrente Y. Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene Mutations. Front Neurol. 2021;12.

Sankhyan N, Sharma S, Choudhary A, Gulati S, Sharma MC, Pathak P, et al. Progressive Weakness in a 12-Year-Old Boy. Journal of Clinical Neuroscience. 2011;18(12):1751.

Yilmaz R, Reisli R, Mücahit TO, Topal A, Uzun ST. Anesthetıc Management of a Pregnant Woman Wıth Lımb-Gırdle Muscular Dystrophy. Journal of Anesthesiology and Reanimation Specialists’ Society. 2019;

Sergin D, Kocabas S, Aşkar FZ, Atay Y. Anesthetic Management in a Patient With Limb Girdle Muscular Dystrophy: Case Report. Turkiye Klinikleri Journal of Anesthesiology Reanimation. 2015;13(2):97–101.

CA J, Somasekar DS, Gurucharan A, Perugu PK, Ashwath S V, Santosh K V. An Uncommon Variant of Rare Type of Muscular Dystrophy. Int J Res Med Sci. 2013;1(3):313.

Kim OMO, Elliott D. Elective Caesarean Section for a Woman With Emery-Dreifuss Muscular Dystrophy. Anaesth Intensive Care. 2010;38(4):744–7.

Emery AEH. Unusual Type of Benign X Linked Muscular Dystrophy. J Neurol Neurosurg Psychiatry. 2012;84(1):4–5.

Takamizawa K, Kim KS, Ueda H. Emery-Dreifuss Muscular Dystrophy With Dilated Cardiomyopathy Preceding Skeletal Muscle Symptoms. Cardiol Young. 2021;32(7):1175–7.

Heller S, Shih R, Kalra R, Kang PB. Emery‐Dreifuss Muscular Dystrophy. Muscle Nerve. 2019;61(4):436–48.

Madej-Pilarczyk A. Clinical Aspects of Emery-Dreifuss Muscular Dystrophy. Nucleus. 2018;9(1):314–20.

Mercuri E, Counsell SJ, Allsop J, Jungbluth H, Kinali M, Bonne G, et al. Selective Muscle Involvement on Magnetic Resonance Imaging in Autosomal Dominant Emery-Dreifuss Muscular Dystrophy. Neuropediatrics. 2002;33(1):10–4.

Mingir T, Berktas CK, Kalyon ST, Turgut N. Facioscapulohumeral Muscular Dystrophy and Anesthesia. The Medical Journal of Okmeydani Training and Research Hospital. 2018;

Xiao T, Yang H, Gan S, Wu L. A Pediatric Case Report and Literature Review of Facioscapulohumeral Muscular Dystrophy Type1. Medicine. 2021;100(47):e27907.

Scionti I, Fabbri G, Fiorillo C, Ricci G, Greco F, D’Amico R, et al. Facioscapulohumeral Muscular Dystrophy: New Insights From Compound Heterozygotes and Implication for Prenatal Genetic Counselling. J Med Genet. 2012;49(3):171–8.

Himeda CL, Jones PL. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy. Annu Rev Genomics Hum Genet. 2019;20(1):265–91.

Ruggiero L, Mele F, Manganelli F, Bruzzese D, Ricci G, Vercelli L, et al. Phenotypic Variability Among Patients With D4Z4 Reduced Allele Facioscapulohumeral Muscular Dystrophy. JAMA Netw Open. 2020;3(5):e204040.

Goselink RJ, Voermans NC, Okkersen K, Brouwer OF, Padberg GW, Nikolić A, et al. Early Onset Facioscapulohumeral Dystrophy – A Systematic Review Using Individual Patient Data. Neuromuscular Disorders. 2017;27(12):1077–83.

Scully MA, Eichinger K, Donlin-Smith CM, Tawil R, Statland J. Restrictive Lung Involvement in Facioscapulohumeral Muscular Dystrophy. Muscle Nerve. 2014;50(5):739–43.

Tawil R, Maarel SM van der. Facioscapulohumeral Muscular Dystrophy. Muscle Nerve. 2006;34(1):1–15.

Mah JK, Chen Y. A Pediatric Review of Facioscapulohumeral Muscular Dystrophy. Journal of Pediatric Neurology. 2017;16(04):222–31.

Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, Engelen BGM v. What’s in a Name? The Clinical Features of Facioscapulohumeral Muscular Dystrophy. Pract Neurol. 2016;16(3):201–7.

Goselink RJ, Schreur V, Kernebeek CR v., Padberg GW, Maarel SM van der, Engelen BGM v., et al. Ophthalmological Findings in Facioscapulohumeral Dystrophy. Brain Commun. 2019;1(1).

Steel D, Main M, Muntoni F, Munot P. Clinical Features of Facioscapulohumeral Muscular Dystrophy 1 in Childhood. Dev Med Child Neurol. 2019;61(8):964–71.

Ekşi MF, Bilgin Mİ, Akyüz AK, Karaca H, Bozo OK, Erbaş O. The Magnificent Quintet of Trinucleotid Repeat Disorders: Spinal and Bulbar Muscular Atrophy, Huntington’s Disease, Friedreich Ataxia, Myotonic Dystrophy, and Fragile X Syndrome. Istanbul Bilim University Florence Nightingale Journal of Medicine. 2019;4(4):219–24.

Atlı Eİ, Gürkan H, Eker D. Hi̇potoni̇ Tanili Çocuk Hastalarda Genom Kopya Sayisi Varyasyonlarinin Önemi̇. 2021;22(4):253–60.

Kumar S, Aroor S, Mundkur SC, Kumar M. Merosin-Deficient Congenital Muscular Dystrophy With Cerebral White Matter Changes: A Clue to Its Diagnosis Beyond Infancy. BMJ Case Rep. 2014;bcr2013202684.

Malpica WSH. Congenital Muscular Dystrophy Due to Merosin Deficiency: Report of a New Mutation. Cureus. 2023;

İncecik F, Hergüner Ö, Ceylaner S, Altunbaşak Ş. Merosin-Negative Congenital Muscular Dystrophy: Report of Five Cases. J Pediatr Neurosci. 2015;10(4):346.

Dimova I, Kremensky I. LAMA2 Congenital Muscle Dystrophy: A Novel Pathogenic Mutation in Bulgarian Patient. Case Rep Genet. 2018;2018:1–3.

Smith SJ, Wang JC, Gupta V, Dowling JJ. A Novel Early Onset Phenotype in a Zebrafish Model of Merosin Deficient Congenital Muscular Dystrophy. PLoS One. 2017;12(2):e0172648.

Eklioğlu BS, Akyürek N, Yuca SA, Atabek ME. Partial Merosin Deficiency and Precocious Puberty. Electronic Journal of General Medicine. 2015;12(1).

Kubota A, Ishiura H, Mitsui J, Sakuishi K, Iwata A, Yamamoto T, et al. A Homozygous &Lt;i>LAMA2</I> Mutation of c.818G>A Caused Partial Merosin Deficiency in a Japanese Patient. Internal Medicine. 2018;57(6):877–82.

Kim HJ, Choi YC, Park HJ, Lee YM, Kim HD, Lee JS, et al. Congenital Muscular Dystrophy Type 1A With Residual Merosin Expression. Korean J Pediatr. 2014;57(3):149.

Lin G, Zhang C, Wang Z, Chan SH, Zhu W, Han C, et al. Congenital Muscular Dystrophies in China. Clin Genet. 2019;96(3):207–15.

Safwat S. Genetic Blueprint of Congenital Muscular Dystrophies With Brain Malformations in Egypt: A Report of 11 Families. Neurogenetics. 2024;25(2):93–102.

Shaharao VB, Agarwal R, Muranjan M, Bavdekar SB. Axonal Involvement With White Matter Abnormalities in Merosin-Positive Congenital Muscular Dystrophy: A New Association. Journal of Pediatric Neurology. 2015;03(03):169–72.

Rajakulendran S, Parton M, Holton JL, Hanna MG. Clinical and Pathological Heterogeneity in Late‐onset Partial Merosin Deficiency. Muscle Nerve. 2011;44(4):590–3.

Yurchenco PD. Integrating Activities of Laminins That Drive Basement Membrane Assembly and Function. 2015;1–30.

Nguyen Q, Lim KRQ, Yokota T. &Lt;p>Current Understanding and Treatment of Cardiac and Skeletal Muscle Pathology in Laminin-Α2 Chain-Deficient Congenital Muscular Dystrophy</P> Appl Clin Genet. 2019;Volume 12:113–30.

Tran VK, Nguyen NL, Tran L, Le PT, Tran AT, Pham TL, et al. Merosin-Deficient Congenital Muscular Dystrophy Type 1a: Detection of LAMA2 Variants in Vietnamese Patients. Front Genet. 2023;14.

Munlemvo DM, Kanaparthi A, Tobias JD. Anesthetic Care of a Child With Merosin-Deficient Muscular Dystrophy. J Med Cases. 2020;11(5):115–9.

Bouchet-Seraphin C, Vuillaumier‐Barrot S, Seta N. Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein. J Neuromuscul Dis. 2015;2(1):27–38.

Ahmed A, Skaria P, Safina NP, Thiffault I, Kats A, Taboada E, et al. Arthrogryposis and Pterygia as Lethal End Manifestations of Genetically Defined Congenital Myopathies. Am J Med Genet A. 2017;176(2):359–67.

Badnaware S. A Rare Case Report of Dental and Craniofacial Manifestations of Nemaline Myopathy. Cureus. 2023;

Watanuki K, Koga H. Case Report: Diagnostic Clues for Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Myopathy in Pediatric Patients. Front Pediatr. 2023;11.

Laughlin RS, Niu Z, Wieben ED, Milone M. RYR1 Causing Distal Myopathy. Mol Genet Genomic Med. 2017;5(6):800–4.

Parr J, Andrew M, Finnis MF, Beeson D, Vincent A, Jayawant S. How Common Is Childhood Myasthenia? The UK Incidence and Prevalence of Autoimmune and Congenital Myasthenia. Arch Dis Child. 2014;99(6):539–42.

Kundu NC, Sen M, Joy KMNI, Quraish FA. Juvenile Myasthenia Gravis: A Case Report and Review of Literatures. Bangladesh Journal of Neuroscience. 2013;29(1):64–9.

Yilmaz S, Gökben S, Serdaroglu G, Akcay A. Early-Onset Acquired Myasthenia Gravis Secondary to Anti–Muscle-Specific Kinase Autoantibodies. J Child Neurol. 2012;29(1):108–10.

Finnis MF, Jayawant S. Juvenile Myasthenia Gravis: A Paediatric Perspective. Autoimmune Dis. 2011;2011:1–7.

O’Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Front Neurol. 2020;11.

Prior DE, Cooper B, Zhang B, Ghosh PS. Developing Outcome Measures of Disease Activity in Pediatric Myasthenia. Muscle Nerve. 2021;63(5):751–7.

Yang L, Tang Y, He F, Zhang C, Kessi M, Peng J, et al. Clinical Characteristics and Outcome Predictors of a Chinese Childhood-Onset Myasthenia Gravis Cohort. Front Pediatr. 2022;10.

Jastrzębska A, Jastrzębski M, Ryniewicz B, Kostera‐Pruszczyk A. Treatment Outcome in Juvenile‐onset Myasthenia Gravis. Muscle Nerve. 2019;59(5):549–54.

Gayfield S, Busken J, Mansur S. A Case Report and 31-Case Study: Does Takotsubo Cardiomyopathy in Myasthenia Gravis Patients Have a High Mortality Rate? Cureus. 2022;

Wendell LC, Levine JM. Myasthenic Crisis. Neurohospitalist. 2011;1(1):16–22.

Batocchi AP, Evoli A, Schino CD, Tonali P. Therapeutic Apheresis in Myasthenia Gravis. Therapeutic Apheresis. 2000;4(4):275–9.

Aydoğan MS, Konur H, Toğal T, Durmuş M, Özgül Ü, Erdoğan M, et al. Myastenik Krizde Noninvaziv Mekanik Ventilasyon Kullanımı. Türk Yoğun Bakım Derneği Dergisi. 2012;10(1):20–2.

Tomak Y, Bostan H, Kazdal H. The Use of Sugammadex in a Patient With Myasthenia Gravis. Turk J Anaesthesiol Reanim. 2011;39(6):341–5.

Öztürk S, Güleç A, Erdoğan M, Demir M, Canpolat M, Gümüş H, et al. Congenital Myasthenic Syndromes in Turkey: Clinical and Molecular Characterization of 16 Cases With Three Novel Mutations. Pediatr Neurol. 2022;136.

Canpolat M, Bayram AK, Bahadir O, Per H, Gümüş H, Dundar M, et al. Clinical Characteristics of Cases With Spinal Muscular Atrophy. Güncel Pediatri. 2016;14(1):18–22.

Saracaloglu A, Demiryürek AT. New Approaches and Approved Drugs in Spinal Muscular Atrophy (SMA) Treatment. Güncel Pediatri. 2021;19(2):248–58.

Korkmaz N. Spinal Muskuler Atrofisi Olan Çocuğun Hemşirelik Bakımı. Yüksek İhtisas Üniversitesi Sağlık Bilimleri Dergisi. 2023;4(2):63–8.

Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Nusinersen Safety and Effects on Motor Function in Adult Spinal Muscular Atrophy Type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91(11):1166–74.

Groen EJN, Talbot K, Gillingwater TH. Advances in Therapy for Spinal Muscular Atrophy: Promises and Challenges. Nat Rev Neurol. 2018;14(4):214–24.

Bjelica B, Wohnrade C, Osmanovic A, Schreiber‐Katz O, Petri S. An Observational Cohort Study on Pulmonary Function in Adult Patients With 5q-Spinal Muscular Atrophy Under Nusinersen Therapy. J Neurol. 2023;270(7):3616–22.

Balci S, Ekinci RMK, Altıntaş DU, Yilmaz M. Juvenile Idiopathic Inflammatory Myopathy: Single Center Data. Cukurova Medical Journal. 2018;43(3):685–91.

Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell KM. Malignant Hyperthermia: A Review. Orphanet J Rare Dis. 2015;10(1).

Cieniewicz A, Trzebicki J, Mayzner-Zawadzka E, Kostera‐Pruszczyk A, Owczuk R. Malignant Hyperthermia – What Do We Know in 2019? Anaesthesiol Intensive Ther. 2019;51(3):169–77.

Klingler W, Heiderich S, Girard T, Gravino E, Heffron JJA, Johannsen S, et al. Functional and Genetic Characterization of Clinical Malignant Hyperthermia Crises: A Multi-Centre Study. Orphanet J Rare Dis. 2014;9(1):8.

Lanner JT. Ryanodine Receptor Physiology and Its Role in Disease. 2012;217–34.

Anwar A, Kyei-Sarpong A, Obodozie J, Lindow SW, Sherif A, Ahmad K. A Case of Thomsen Disease in Pregnancy: Case Report. Open J Obstet Gynecol. 2019;09(02):136–41.

Tunçer GÖ, Sanrı A, AYDIN S, Hergüner Ö, Özgün N, Kömür M, et al. Clinical and Genetic Spectrum of Myotonia Congenita in Turkish Children. J Neuromuscul Dis. 2023;10(5):915–24.

Marinakis NM. Myotonia Congenita in a Greek Cohort: Genotype Spectrum and Impact of the CLCN1:c.501C > G Variant as a Genetic Modifier. Muscle Nerve. 2024;70(2):240–7.

Gündüz NE. Activity Limitation and Functional Assessment in Neuromuscular Diseases: Results of a Tertiary Center. Fiziksel Tıp Ve Rehabilitasyon Bilimleri Dergisi. 2023;26(2):199–205.

Yeldan İ, Aslan GK. Nöromusküler Hastalıklarda Solunum Fonksiyonlarının Değerlendirilmesi: Derleme. Sağlık Bilimleri Ve Meslekleri Dergisi. 2014;1(2):127.

Molotsky E, Liu Y, Lieberman AP, Merry DE. Neuromuscular Junction Pathology Is Correlated With Differential Motor Unit Vulnerability in Spinal and Bulbar Muscular Atrophy. Acta Neuropathol Commun. 2022;10(1).

Monti RJ, Roy RR, Edgerton VR. Role of Motor Unit Structure in Defining Function. Muscle Nerve. 2001;24(7):848–66.

Rocha MC, Pousinha PA, Correia A, Sebastião AM, Ribeiro JA. Early Changes of Neuromuscular Transmission in the SOD1(G93A) Mice Model of ALS Start Long Before Motor Symptoms Onset. PLoS One. 2013;8(9):e73846.

Tintignac L, Brenner HR, Rüegg MA. Mechanisms Regulating Neuromuscular Junction Development and Function and Causes of Muscle Wasting. Physiol Rev. 2015;95(3):809–52.

Ortíz-Benítez RE, Carrillo-Torres O, Mendoza-Escoto VM, Garduño-Prevost P, Alcazar-Castro J. Perioperative Management of the Patient With Myasthenia Gravis. Revista Médica del Hospital General de México. 2019;82(2).

Pollitt C, Anderson L V, Pogue R, Davison K, Pyle A, Bushby K. The Phenotype of Calpainopathy: Diagnosis Based on a Multidisciplinary Approach. Neuromuscular Disorders. 2001;11(3):287–96.

Bushby K, Finkel RS, Birnkrant DJ, Case LE, Clemens PR, Cripe LH, et al. Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Pharmacological and Psychosocial Management. Lancet Neurol. 2010;9(1):77–93.

Nance J. Spinal Muscular Atrophy. Continuum Lifelong Learning in Neurology. 2020;26(5):1348–68.

VanderPluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical Characteristics of Pediatric Myasthenia: A Surveillance Study. Pediatrics. 2013;132(4):e939–44.

Daack-Hirsch S, Holtzer C, Cunniff C. Parental Perspectives on the Diagnostic Process for Duchenne and Becker Muscular Dystrophy. Am J Med Genet A. 2013;161(4):687–95.

Jones TI, Yan C, Sapp PC, McKenna‐Yasek D, Kang PB, Quinn C, et al. Identifying Diagnostic DNA Methylation Profiles for Facioscapulohumeral Muscular Dystrophy in Blood and Saliva Using Bisulfite Sequencing. Clin Epigenetics. 2014;6(1).

Segarra-Casas A, Domínguez‐González C, Hernández-Laín A, Sánchez-Calvín MT, Camacho A, Rivas E, et al. Genetic Diagnosis of Duchenne and Becker Muscular Dystrophy Through mRNA Analysis: New Splicing Events. J Med Genet. 2022;60(6):615–9.

Ricci G, Mele F, Govi M, Ruggiero L, Sera F, Vercelli L, et al. Large Genotype–phenotype Study in Carriers of D4Z4 Borderline Alleles Provides Guidance for Facioscapulohumeral Muscular Dystrophy Diagnosis. Sci Rep. 2020;10(1).

Nahrel DR, Kosam D. Duchenne Muscular Dystrophy in a Female Child With Turner Syndrome: A Case Report. International Journal of Medical Research and Review. 2014;2(3):262–6.

Pane M, Scalise R, Berardinelli A, D’Angelo MG, Ricotti V, Alfieri P, et al. Early Neurodevelopmental Assessment in Duchenne Muscular Dystrophy. Neuromuscular Disorders. 2013;23(6):451–5.

Hendawy MTE, Marzouk I, Omr TE, Elmaksoud MA. Quality of Life Assessment in Patients With Duchenne Muscular Dystrophy. Int J Health Sci (Qassim). 2022;15040–9.

Koeks Z, Bladen CL, Salgado D, Zwet EW v., Pogoryelova O, McMacken G, et al. Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients From the TREAT-NMD DMD Global Database. J Neuromuscul Dis. 2017;4(4):293–306.

Kern R, Carvell K, Gupta A, Verma S. Seated Outcome Measures in Children With Duchenne Muscular Dystrophy. Pediatric Physical Therapy. 2022;34(3):375–80.

Soim A, Wallace B, Whitehead N, Smith MGH, Mann JR, Thomas S, et al. Health Profile of Preterm Males With Duchenne Muscular Dystrophy. J Child Neurol. 2021;36(12):1095–102.

Parvatiyar MS, Marshall JL, Nguyen RT, Jordan MC, Richardson VA, Roos KP, et al. Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy–Associated Cardiomyopathy. J Am Heart Assoc. 2015;4(12).

Fox D, Kumar A, West NA, DiRienzo AG, James KA, Oleszek J. Trends With Corticosteroid Use in Males With Duchenne Muscular Dystrophy Born 1982-2001. J Child Neurol. 2014;30(1):21–6.

Ryder S, Leadley RM, Armstrong N, Westwood M, Kock S d., Butt T, et al. The Burden, Epidemiology, Costs and Treatment for Duchenne Muscular Dystrophy: An Evidence Review. Orphanet J Rare Dis. 2017;12(1).

Biggar WD, Skalsky AJ, McDonald C. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2022;9(4):463–76.

Liaqat ST. Overview of Muscular Dystrophy, It’s Types, Symptoms, Management and Possible Treatment. Pure and Applied Biology. 2023;12(1).

Butterfield RJ, Krikov S, Conway KM, Johnson NE, Matthews DJ, Phan H, et al. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet. Muscle Nerve. 2022;66(1):15–23.

Danišovič Ľ, Culenova M, Csöbönyeiová M. Induced Pluripotent Stem Cells for Duchenne Muscular Dystrophy Modeling and Therapy. Cells. 2018;7(12):253.

Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes L, Miller N, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy. JAMA Neurol. 2020;77(9):1122.

Mbakam CH, Lamothe G, Tremblay JP. Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy. Front Med (Lausanne). 2022;9.

Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. Muscle Nerve [Internet]. 2024 Jan 1 [cited 2025 Jan 1];69(1):93–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.27955

McMillan HJ, Lochmüller H. Sustained clinical benefit following systemic gene replacement therapy in Duchenne muscular dystrophy. Muscle Nerve. 2024 Jan 1;69(1):4–6.

Šamija RK, Plejić M. Duchenne Muscular Dystrophy: Clinical and Therapeutic Approach. 2023;

Yoon JA, Park HE, Kim J, Son J, Shin YB. Cardiac and Pulmonary Management Status of Duchenne Muscular Dystrophy in South Korea Based on Data From the National Health Insurance Database. Journal of Clinical Neurology. 2022;18(5):522.

Bennett JS, Kertesz NJ. Management of Rhythm Disorders in Duchenne Muscular Dystrophy: Is Sudden Death a Cardiac or Pulmonary Problem? Pediatr Pulmonol. 2021;56(4):760–5.

Komaki H, Maegaki Y, Matsumura T, Shiraishi K, Awano H, Nakamura A, et al. Early Phase 2 Trial of TAS‐205 in Patients With Duchenne Muscular Dystrophy. Ann Clin Transl Neurol. 2020;7(2):181–90.

Pascual‐Morena C, Cavero‐Redondo I, Álvarez‐Bueno C, Mesas AE, Pozuelo‐Carrascosa DP, Martínez‐Vizcaíno V. Restorative Treatments of Dystrophin Expression in Duchenne Muscular Dystrophy: A Systematic Review. Ann Clin Transl Neurol. 2020;7(9):1738–52.

Köken ÖY, Kucur O, Taşkiran C, Öztoprak Ü, Sel ÇG, Aksoy E, et al. Clinical Features and Quality of Life in Duchenne and Becker Muscular Dystrophy Patients From a Tertiary Center in Turkey. Güncel Pediatri. 2021;19(1):15–22.

Magot A. Diagnosis and Management of Becker Muscular Dystrophy: The French Guidelines. J Neurol. 2023;270(10):4763–81.

Clemens PR. Findings From the Longitudinal CINRG Becker Natural History Study. J Neuromuscul Dis. 2024;11(1):201–12.

Aikawa T, Takeda A, Oyama‐Manabe N, Naya M, Yamazawa H, Koyanagawa K, et al. Progressive Left Ventricular Dysfunction and Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy: A Longitudinal Cardiovascular Magnetic Resonance Study. Pediatr Cardiol. 2018;40(2):384–92.

Canessa EH, Goswami M V, Alayi TD, Hoffman EP, Hathout Y. Absolute Quantification of Dystrophin Protein in Human Muscle Biopsies Using Parallel Reaction Monitoring (PRM). Biol Mass Spectrom. 2019;55(2).

Lee AY, Moon JW, Yü J, Kho C. MicroRNAs in Dystrophinopathy. Int J Mol Sci. 2022;23(14):7785.

Birnkrant DJ, Bushby K, Bann C, Alman BA, Apkon S, Blackwell AG, et al. Diagnosis and Management of Duchenne Muscular Dystrophy, Part 2: Respiratory, Cardiac, Bone Health, and Orthopaedic Management. Lancet Neurol. 2018;17(4):347–61.

Woodcock IR, Fraser L, Norman P, Pysden K, Manning S, Childs A. The Prevalence of Neuromuscular Disease in the Paediatric Population in Yorkshire, UK; Variation by Ethnicity and Deprivation Status. Dev Med Child Neurol. 2016;58(8):877–83.

Lai Y, Duan D. Progress in Gene Therapy of Dystrophic Heart Disease. Gene Ther. 2012;19(6):678–85.

Kuno A, Tanno M, Horio Y. The Effects of Resveratrol and SIRT1 Activation on Dystrophic Cardiomyopathy. Ann N Y Acad Sci. 2015;1348(1):46–54.

Lambert JT, Darmahkasih A, Horn PS, Rybalsky I, Shellenbarger K, Tian C, et al. Neurodevelopmental, Behavioral, and Emotional Symptoms in Becker Muscular Dystrophy. Muscle Nerve. 2019;61(2):156–62.

Laurila P, Luan P, Wohlwend M, Zanou N, Crisol BM, Lima TI, et al. Inhibition of Sphingolipid De Novo Synthesis Counteracts Muscular Dystrophy. Sci Adv. 2022;8(4).

Pezzoni L. Cognitive Abnormalities in Becker Muscular Dystrophy: A Mysterious Link Between Dystrophin Deficiency and Executive Functions. Neurological Sciences. 2023;45(4):1691–8.

Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, et al. The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia. Hum Mutat. 2013;34(11):1449–57.

Burch PM, Pogoryelova O, Goldstein RA, Bennett D, Guglieri M, Straub V, et al. Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy. J Neuromuscul Dis. 2015;2(3):241–55.

Takeuchi F, Komaki H, Nakamura H, Yonemoto N, Kashiwabara K, Kimura E, et al. Trends in Steroid Therapy for Duchenne Muscular Dystrophy in Japan. Muscle Nerve. 2016;54(4):673–80.

Barreo FS. Targeted Suppression of a Dystrophin Pseudo-Exon Using Antisense Oligonucleotides. J Genet Syndr Gene Ther. 2014;05(04).

Marden JR, Santos C, Pfister B, Able R, Lane HC, Somma M, et al. Steroid Switching in Dystrophinopathy Treatment: A US chart Review of Patient Characteristics and Clinical Outcomes. J Comp Eff Res. 2021;10(14):1065–78.

McDonald C, Sajeev G, Yao Z, McDonnell E, Elfring GL, Souza MF d., et al. Deflazacort vs Prednisone Treatment for Duchenne Muscular Dystrophy: A Meta‐analysis of Disease Progression Rates in Recent Multicenter Clinical Trials. Muscle Nerve. 2019;61(1):26–35.

Dubinin M V, Talanov EY, Tenkov KS, Starinets VS, Belosludtseva N V, Belosludtsev KN. The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy. Int J Mol Sci. 2020;21(22):8763.

Hoffman EP, Reeves EK, Damsker JM, Nagaraju K, McCall JM, Connor E, et al. Novel Approaches to Corticosteroid Treatment in Duchenne Muscular Dystrophy. Phys Med Rehabil Clin N Am. 2012;23(4):821–8.

Yilmaz A, Gökçeoğlu AU, Talim B, Bakir A, ATAY N. Limb Girdle Muskuler Distrofi Tip 2a: Vaka Sunumu. Turkish Journal of Pediatric Disease. 2022;1–4.

Ullah A, Lin Z, Younus M, Shafiq S, Khan S, Rasheed M, et al. Homozygous Missense Variant in POPDC3 Causes Recessive Limb‐girdle Muscular Dystrophy Type 26. J Gene Med. 2022;24(4).

Barton ER, Pacak CA, Stoppel WL, Kang PB. The Ties That Bind: Functional Clusters in Limb-Girdle Muscular Dystrophy. Skelet Muscle. 2020;10(1).

Zhang C, Zheng X, Lyu D, Xu L, Che F, Liu S. Compound heterozygous CAPN3 variants identified in a family with limb-girdle muscular dystrophy recessive 1. Mol Med Rep. 2021;23(6).

Becker N, Moore SA, Jones KA. The Inflammatory Pathology of Dysferlinopathy Is Distinct From Calpainopathy, Becker Muscular Dystrophy, and Inflammatory Myopathies. Acta Neuropathol Commun. 2022;10(1).

Marchetti G, Valenti L, Torrente Y. Clinical Determinants of Disease Progression in Patients With Beta-Sarcoglycan Gene Mutations. Front Neurol. 2021;12.

Sankhyan N, Sharma S, Choudhary A, Gulati S, Sharma MC, Pathak P, et al. Progressive Weakness in a 12-Year-Old Boy. Journal of Clinical Neuroscience. 2011;18(12):1751.

Yilmaz R, Reisli R, Mücahit TO, Topal A, Uzun ST. Anesthetıc Management of a Pregnant Woman Wıth Lımb-Gırdle Muscular Dystrophy. Journal of Anesthesiology and Reanimation Specialists’ Society. 2019;

Sergin D, Kocabas S, Aşkar FZ, Atay Y. Anesthetic Management in a Patient With Limb Girdle Muscular Dystrophy: Case Report. Turkiye Klinikleri Journal of Anesthesiology Reanimation. 2015;13(2):97–101.

CA J, Somasekar DS, Gurucharan A, Perugu PK, Ashwath S V, Santosh K V. An Uncommon Variant of Rare Type of Muscular Dystrophy. Int J Res Med Sci. 2013;1(3):313.

Kim OMO, Elliott D. Elective Caesarean Section for a Woman With Emery-Dreifuss Muscular Dystrophy. Anaesth Intensive Care. 2010;38(4):744–7.

Emery AEH. Unusual Type of Benign X Linked Muscular Dystrophy. J Neurol Neurosurg Psychiatry. 2012;84(1):4–5.

Takamizawa K, Kim KS, Ueda H. Emery-Dreifuss Muscular Dystrophy With Dilated Cardiomyopathy Preceding Skeletal Muscle Symptoms. Cardiol Young. 2021;32(7):1175–7.

Heller S, Shih R, Kalra R, Kang PB. Emery‐Dreifuss Muscular Dystrophy. Muscle Nerve. 2019;61(4):436–48.

Madej-Pilarczyk A. Clinical Aspects of Emery-Dreifuss Muscular Dystrophy. Nucleus. 2018;9(1):314–20.

Mercuri E, Counsell SJ, Allsop J, Jungbluth H, Kinali M, Bonne G, et al. Selective Muscle Involvement on Magnetic Resonance Imaging in Autosomal Dominant Emery-Dreifuss Muscular Dystrophy. Neuropediatrics. 2002;33(1):10–4.

Mingir T, Berktas CK, Kalyon ST, Turgut N. Facioscapulohumeral Muscular Dystrophy and Anesthesia. The Medical Journal of Okmeydani Training and Research Hospital. 2018;

Xiao T, Yang H, Gan S, Wu L. A Pediatric Case Report and Literature Review of Facioscapulohumeral Muscular Dystrophy Type1. Medicine. 2021;100(47):e27907.

Scionti I, Fabbri G, Fiorillo C, Ricci G, Greco F, D’Amico R, et al. Facioscapulohumeral Muscular Dystrophy: New Insights From Compound Heterozygotes and Implication for Prenatal Genetic Counselling. J Med Genet. 2012;49(3):171–8.

Himeda CL, Jones PL. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy. Annu Rev Genomics Hum Genet. 2019;20(1):265–91.

Ruggiero L, Mele F, Manganelli F, Bruzzese D, Ricci G, Vercelli L, et al. Phenotypic Variability Among Patients With D4Z4 Reduced Allele Facioscapulohumeral Muscular Dystrophy. JAMA Netw Open. 2020;3(5):e204040.

Goselink RJ, Voermans NC, Okkersen K, Brouwer OF, Padberg GW, Nikolić A, et al. Early Onset Facioscapulohumeral Dystrophy – A Systematic Review Using Individual Patient Data. Neuromuscular Disorders. 2017;27(12):1077–83.

Scully MA, Eichinger K, Donlin-Smith CM, Tawil R, Statland J. Restrictive Lung Involvement in Facioscapulohumeral Muscular Dystrophy. Muscle Nerve. 2014;50(5):739–43.

Tawil R, Maarel SM van der. Facioscapulohumeral Muscular Dystrophy. Muscle Nerve. 2006;34(1):1–15.

Mah JK, Chen Y. A Pediatric Review of Facioscapulohumeral Muscular Dystrophy. Journal of Pediatric Neurology. 2017;16(04):222–31.

Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, Engelen BGM v. What’s in a Name? The Clinical Features of Facioscapulohumeral Muscular Dystrophy. Pract Neurol. 2016;16(3):201–7.

Goselink RJ, Schreur V, Kernebeek CR v., Padberg GW, Maarel SM van der, Engelen BGM v., et al. Ophthalmological Findings in Facioscapulohumeral Dystrophy. Brain Commun. 2019;1(1).

Steel D, Main M, Muntoni F, Munot P. Clinical Features of Facioscapulohumeral Muscular Dystrophy 1 in Childhood. Dev Med Child Neurol. 2019;61(8):964–71.

Ekşi MF, Bilgin Mİ, Akyüz AK, Karaca H, Bozo OK, Erbaş O. The Magnificent Quintet of Trinucleotid Repeat Disorders: Spinal and Bulbar Muscular Atrophy, Huntington’s Disease, Friedreich Ataxia, Myotonic Dystrophy, and Fragile X Syndrome. Istanbul Bilim University Florence Nightingale Journal of Medicine. 2019;4(4):219–24.

Atlı Eİ, Gürkan H, Eker D. Hi̇potoni̇ Tanili Çocuk Hastalarda Genom Kopya Sayisi Varyasyonlarinin Önemi̇. 2021;22(4):253–60.

Kumar S, Aroor S, Mundkur SC, Kumar M. Merosin-Deficient Congenital Muscular Dystrophy With Cerebral White Matter Changes: A Clue to Its Diagnosis Beyond Infancy. BMJ Case Rep. 2014;bcr2013202684.

Malpica WSH. Congenital Muscular Dystrophy Due to Merosin Deficiency: Report of a New Mutation. Cureus. 2023;

İncecik F, Hergüner Ö, Ceylaner S, Altunbaşak Ş. Merosin-Negative Congenital Muscular Dystrophy: Report of Five Cases. J Pediatr Neurosci. 2015;10(4):346.

Dimova I, Kremensky I. LAMA2 Congenital Muscle Dystrophy: A Novel Pathogenic Mutation in Bulgarian Patient. Case Rep Genet. 2018;2018:1–3.

Smith SJ, Wang JC, Gupta V, Dowling JJ. A Novel Early Onset Phenotype in a Zebrafish Model of Merosin Deficient Congenital Muscular Dystrophy. PLoS One. 2017;12(2):e0172648.

Eklioğlu BS, Akyürek N, Yuca SA, Atabek ME. Partial Merosin Deficiency and Precocious Puberty. Electronic Journal of General Medicine. 2015;12(1).

Kubota A, Ishiura H, Mitsui J, Sakuishi K, Iwata A, Yamamoto T, et al. A Homozygous &Lt;i>LAMA2</I> Mutation of c.818G>A Caused Partial Merosin Deficiency in a Japanese Patient. Internal Medicine. 2018;57(6):877–82.

Kim HJ, Choi YC, Park HJ, Lee YM, Kim HD, Lee JS, et al. Congenital Muscular Dystrophy Type 1A With Residual Merosin Expression. Korean J Pediatr. 2014;57(3):149.

Lin G, Zhang C, Wang Z, Chan SH, Zhu W, Han C, et al. Congenital Muscular Dystrophies in China. Clin Genet. 2019;96(3):207–15.

Safwat S. Genetic Blueprint of Congenital Muscular Dystrophies With Brain Malformations in Egypt: A Report of 11 Families. Neurogenetics. 2024;25(2):93–102.

Shaharao VB, Agarwal R, Muranjan M, Bavdekar SB. Axonal Involvement With White Matter Abnormalities in Merosin-Positive Congenital Muscular Dystrophy: A New Association. Journal of Pediatric Neurology. 2015;03(03):169–72.

Rajakulendran S, Parton M, Holton JL, Hanna MG. Clinical and Pathological Heterogeneity in Late‐onset Partial Merosin Deficiency. Muscle Nerve. 2011;44(4):590–3.

Yurchenco PD. Integrating Activities of Laminins That Drive Basement Membrane Assembly and Function. 2015;1–30.

Nguyen Q, Lim KRQ, Yokota T. &Lt;p>Current Understanding and Treatment of Cardiac and Skeletal Muscle Pathology in Laminin-Α2 Chain-Deficient Congenital Muscular Dystrophy</P> Appl Clin Genet. 2019;Volume 12:113–30.

Tran VK, Nguyen NL, Tran L, Le PT, Tran AT, Pham TL, et al. Merosin-Deficient Congenital Muscular Dystrophy Type 1a: Detection of LAMA2 Variants in Vietnamese Patients. Front Genet. 2023;14.

Munlemvo DM, Kanaparthi A, Tobias JD. Anesthetic Care of a Child With Merosin-Deficient Muscular Dystrophy. J Med Cases. 2020;11(5):115–9.

Bouchet-Seraphin C, Vuillaumier‐Barrot S, Seta N. Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein. J Neuromuscul Dis. 2015;2(1):27–38.

Ahmed A, Skaria P, Safina NP, Thiffault I, Kats A, Taboada E, et al. Arthrogryposis and Pterygia as Lethal End Manifestations of Genetically Defined Congenital Myopathies. Am J Med Genet A. 2017;176(2):359–67.

Badnaware S. A Rare Case Report of Dental and Craniofacial Manifestations of Nemaline Myopathy. Cureus. 2023;

Watanuki K, Koga H. Case Report: Diagnostic Clues for Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Myopathy in Pediatric Patients. Front Pediatr. 2023;11.

Laughlin RS, Niu Z, Wieben ED, Milone M. RYR1 Causing Distal Myopathy. Mol Genet Genomic Med. 2017;5(6):800–4.

Parr J, Andrew M, Finnis MF, Beeson D, Vincent A, Jayawant S. How Common Is Childhood Myasthenia? The UK Incidence and Prevalence of Autoimmune and Congenital Myasthenia. Arch Dis Child. 2014;99(6):539–42.

Kundu NC, Sen M, Joy KMNI, Quraish FA. Juvenile Myasthenia Gravis: A Case Report and Review of Literatures. Bangladesh Journal of Neuroscience. 2013;29(1):64–9.

Yilmaz S, Gökben S, Serdaroglu G, Akcay A. Early-Onset Acquired Myasthenia Gravis Secondary to Anti–Muscle-Specific Kinase Autoantibodies. J Child Neurol. 2012;29(1):108–10.

Finnis MF, Jayawant S. Juvenile Myasthenia Gravis: A Paediatric Perspective. Autoimmune Dis. 2011;2011:1–7.

O’Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Front Neurol. 2020;11.

Prior DE, Cooper B, Zhang B, Ghosh PS. Developing Outcome Measures of Disease Activity in Pediatric Myasthenia. Muscle Nerve. 2021;63(5):751–7.

Yang L, Tang Y, He F, Zhang C, Kessi M, Peng J, et al. Clinical Characteristics and Outcome Predictors of a Chinese Childhood-Onset Myasthenia Gravis Cohort. Front Pediatr. 2022;10.

Jastrzębska A, Jastrzębski M, Ryniewicz B, Kostera‐Pruszczyk A. Treatment Outcome in Juvenile‐onset Myasthenia Gravis. Muscle Nerve. 2019;59(5):549–54.

Gayfield S, Busken J, Mansur S. A Case Report and 31-Case Study: Does Takotsubo Cardiomyopathy in Myasthenia Gravis Patients Have a High Mortality Rate? Cureus. 2022;

Wendell LC, Levine JM. Myasthenic Crisis. Neurohospitalist. 2011;1(1):16–22.

Batocchi AP, Evoli A, Schino CD, Tonali P. Therapeutic Apheresis in Myasthenia Gravis. Therapeutic Apheresis. 2000;4(4):275–9.

Aydoğan MS, Konur H, Toğal T, Durmuş M, Özgül Ü, Erdoğan M, et al. Myastenik Krizde Noninvaziv Mekanik Ventilasyon Kullanımı. Türk Yoğun Bakım Derneği Dergisi. 2012;10(1):20–2.

Tomak Y, Bostan H, Kazdal H. The Use of Sugammadex in a Patient With Myasthenia Gravis. Turk J Anaesthesiol Reanim. 2011;39(6):341–5.

Öztürk S, Güleç A, Erdoğan M, Demir M, Canpolat M, Gümüş H, et al. Congenital Myasthenic Syndromes in Turkey: Clinical and Molecular Characterization of 16 Cases With Three Novel Mutations. Pediatr Neurol. 2022;136.

Canpolat M, Bayram AK, Bahadir O, Per H, Gümüş H, Dundar M, et al. Clinical Characteristics of Cases With Spinal Muscular Atrophy. Güncel Pediatri. 2016;14(1):18–22.

Saracaloglu A, Demiryürek AT. New Approaches and Approved Drugs in Spinal Muscular Atrophy (SMA) Treatment. Güncel Pediatri. 2021;19(2):248–58.

Korkmaz N. Spinal Muskuler Atrofisi Olan Çocuğun Hemşirelik Bakımı. Yüksek İhtisas Üniversitesi Sağlık Bilimleri Dergisi. 2023;4(2):63–8.

Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Nusinersen Safety and Effects on Motor Function in Adult Spinal Muscular Atrophy Type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91(11):1166–74.

Groen EJN, Talbot K, Gillingwater TH. Advances in Therapy for Spinal Muscular Atrophy: Promises and Challenges. Nat Rev Neurol. 2018;14(4):214–24.

Bjelica B, Wohnrade C, Osmanovic A, Schreiber‐Katz O, Petri S. An Observational Cohort Study on Pulmonary Function in Adult Patients With 5q-Spinal Muscular Atrophy Under Nusinersen Therapy. J Neurol. 2023;270(7):3616–22.

Balci S, Ekinci RMK, Altıntaş DU, Yilmaz M. Juvenile Idiopathic Inflammatory Myopathy: Single Center Data. Cukurova Medical Journal. 2018;43(3):685–91.

Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell KM. Malignant Hyperthermia: A Review. Orphanet J Rare Dis. 2015;10(1).

Cieniewicz A, Trzebicki J, Mayzner-Zawadzka E, Kostera‐Pruszczyk A, Owczuk R. Malignant Hyperthermia – What Do We Know in 2019? Anaesthesiol Intensive Ther. 2019;51(3):169–77.

Klingler W, Heiderich S, Girard T, Gravino E, Heffron JJA, Johannsen S, et al. Functional and Genetic Characterization of Clinical Malignant Hyperthermia Crises: A Multi-Centre Study. Orphanet J Rare Dis. 2014;9(1):8.

Lanner JT. Ryanodine Receptor Physiology and Its Role in Disease. 2012;217–34.

Anwar A, Kyei-Sarpong A, Obodozie J, Lindow SW, Sherif A, Ahmad K. A Case of Thomsen Disease in Pregnancy: Case Report. Open J Obstet Gynecol. 2019;09(02):136–41.

Tunçer GÖ, Sanrı A, AYDIN S, Hergüner Ö, Özgün N, Kömür M, et al. Clinical and Genetic Spectrum of Myotonia Congenita in Turkish Children. J Neuromuscul Dis. 2023;10(5):915–24.

Marinakis NM. Myotonia Congenita in a Greek Cohort: Genotype Spectrum and Impact of the CLCN1:c.501C > G Variant as a Genetic Modifier. Muscle Nerve. 2024;70(2):240–7.